Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Zhenlong Xingnao Medicinal Composition in Preparation of Drugs for Treating Diabetic Peripheral Neuropathy

A peripheral neuropathy, Zhenlong refreshing technology, applied in the field of medicine, can solve the problems of no safe and effective treatment method, difficult treatment of diabetic neuropathy, etc., and achieve the effect of remarkable curative effect and wide clinical application.

Active Publication Date: 2015-11-18
JINKE TIBETAN MEDICINE QINGHAI PROV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of diabetic neuropathy is still difficult, so far there is no safe and effective treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Zhenlong Xingnao Medicinal Composition in Preparation of Drugs for Treating Diabetic Peripheral Neuropathy
  • Application of Zhenlong Xingnao Medicinal Composition in Preparation of Drugs for Treating Diabetic Peripheral Neuropathy
  • Application of Zhenlong Xingnao Medicinal Composition in Preparation of Drugs for Treating Diabetic Peripheral Neuropathy

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0020] Experimental example 1, preparation of active ingredients of Zhenlong Xinnao medicinal composition

[0021] Prescription: pearl 17.3g, geranium 2.2g, saffron 8.7g, clove 9.7g, nutmeg 8.7g, cardamom 8.7g, grass fruit 6.5g, sandalwood 8.7g, red sandalwood 21.6g, agarwood 17.3g, chrysanthemum 28.1g of chevron, 17.3g of myrobalan, 21.6g of emblica, 21.6g of woody fragrance, 17.3g of cinnamon, 8.7g of Piperium, 10.8g of crab, 8.7g of golden stone, 5.4g of parsley, 2.2g of artificial bezoar, Musk 2.2g, Jujube 6.5g, Rhododendron 6.5g, Corydalis 13.0g, Rabbit ear grass 43.3g, Iron powder (manufactured) 4.3g, Mallow fruit 17.3g, Licorice 13.0g, Nigella seeds 5.4g;

[0022] The saffron, artificial bezoar, and musk were mixed and ground into fine powder for later use. The remaining 26 medicinal materials were extracted with 90% ethanol as a solvent at 50°C. The number of extractions was 3 times, and each extraction time was 3 hours. The amount of solvent used each time is 20 tim...

experiment example 2

[0030] Experimental example 2, pharmacological experiment for treating DPN

[0031] 1. Drugs and instruments: Streptozotocin (STZ) product of Sigma Chemical Company of the United States; Zhenlong Xinnao Capsule (Qinghai Jinhe Tibetan Medicine Co., Ltd., batch number 20120806); Zhenlong Xinnao pharmaceutical composition (method in Example 1) Preparation, batch number: 20121219), IL-B electric stimulator, SR46 second-line oscilloscope (Shanghai Radio 21 Factory).

[0032] 2. Modeling method: use Wistar male rats, weighing 250-300 g, about 10 weeks old. Use 0.1mol / L citric acid buffer (pH=4.4) to freshly prepare STZ solution with 0.1mol / L sterile citric acid-sodium citrate buffer to make a 2% solution. kg tail vein injection, fasting blood glucose (FBG) was measured 7 days after administration, and those with fasting blood glucose above 15mmol / L were DPN rats.

[0033] 3. Grouping: the rats were randomly divided into 4 groups, 15 in each group: control group, model group, Zhenl...

experiment example 3

[0050] 1. Clinical data

[0051] 102 patients with DPN were randomly divided into treatment group A of 34 cases, including 16 males and 18 females; aged 29 to 67 years, with a course of disease of 2 to 8 years; treatment B group of 34 cases, including 17 males and 17 females; Aged 27 to 65 years old, course of disease 3 to 9 years. The control group included 34 cases, including 15 males and 19 females; aged 26 to 68 years, with a course of disease ranging from 0.5 to 7 years. 2 cases in treatment group A, 1 case in treatment group B, and 2 cases in control group were lost to follow-up during the treatment period.

[0052] 2. Diagnostic criteria

[0053] 2.1 Western medicine diagnostic criteria: ①according to the ADA diagnostic criteria for diabetes (1997); ②persistent pain and / or paresthesia in limbs (at least in both lower extremities); ③decreased bilateral or unilateral ankle reflexes; ④decreased vibration sensation ( The medial malleolus is weaker than the medial tibia);...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the application of Zhenlong Xingnao medicinal composition in the preparation of medicines for treating diabetic peripheral neuropathy. Zhenlong Xingnao Preparation is traditionally used in the treatment of acute cerebral infarction, carotid atherosclerotic plaque, and stroke sequelae. The present invention proves through pharmacological experiments and clinical observations that Zhenlong Xingnao medicinal composition, including Zhenlong Xingnao capsule and Zhenlong Xinnao medicinal composition prepared by improved process, can significantly improve the symptoms of the nervous system of DPN patients, and can Significantly increase the nerve conduction velocity, improve a variety of biochemical indicators, and can be used for the treatment and prevention of DPN.

Description

technical field [0001] The invention relates to the application of a Zhenlong brain-invigorating pharmaceutical composition in the preparation of medicines for treating diabetic peripheral neuropathy, and belongs to the field of medicine. Background technique [0002] Zhenlong Xingnao Capsule is recorded in the national drug standard part of the local standard increase of Chinese patent medicine (internal medicine brain system, meridian and limb sub-volume), standard number: WS-10708(ZD-0708)-2002. Zhenlong Xinnao Capsules are composed of pearl, geranium yellow, saffron, clove, nutmeg, cardamom, grass fruit, sandalwood, red sandalwood, agarwood, myrobalan, myrobalan, emblica, woody fragrance, cinnamon, longan It is made of 29 medicinal materials such as , crab, golden stone, and parsley. It has the effects of resuscitating the mind, clearing away heat and dredging the collaterals. After years of clinical verification, the curative effect is remarkable. [0003] Diabetic ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/9064A61P3/10A61P25/02A61K33/06A61K33/26A61K35/413A61K35/55A61K35/618A61K35/612
Inventor 李敏刘玉芹郑亭亭王悦任松鹏
Owner JINKE TIBETAN MEDICINE QINGHAI PROV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com